Skip to main navigation Skip to search Skip to main content

Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis

  • Catherine Shelton
  • , Matthew McNeil
  • , Renee Allen
  • , Lindsay Flint
  • , Dara Russell
  • , Bryan Berube
  • , Aaron Korkegian
  • , Yulia Ovechkina
  • , Tanya Parish
  • Infectious Disease Research Institute
  • Seattle Children's Hospital

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

We previously identified a series of triazolopyrimidines with antitubercular activity. We determined that Mycobacterium tuberculosis strains with mutations in QcrB, a subunit of the cytochrome bcc-aa3 supercomplex, were resistant. A cytochrome bd oxidase deletion strain was more sensitive to this series. We isolated resistant mutants with mutations in Rv1339. Compounds led to the depletion of intracellular ATP levels and were active against intracellular bacteria, but they did not inhibit human mitochondrial respiration. These data are consistent with triazolopyrimidines acting via inhibition of QcrB.

Original languageEnglish
Article numbere02041-21
JournalAntimicrobial Agents and Chemotherapy
Volume66
Issue number4
DOIs
Publication statusPublished - 9 Mar 2022
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • aerobic respiration
  • antibiotic resistance
  • antibiotic tolerance
  • tuberculosis

Fingerprint

Dive into the research topics of 'Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this